Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Elon Musk Becomes World's First Trillionaire After SpaceX IPO Surge 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Trump Says Anthropic No Longer Seen as National Security Threat 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Anthropic Officials Meet White House Over AI Model Outage 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Meta AI Strategy Faces Challenges as Zuckerberg Admits Mistakes in Internal Memo 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Hanmi Semicon Shares Surge After $33 Million SpaceX Investment 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the site's inauguration, confirmed plans for further investments in the coming years.
The Hyderabad facility, announced last year, aims to accelerate medicine development through cutting-edge technology. By year-end, it is expected to employ 2,000 people, with 300 already on board, according to Som Chattopadhyay, Amgen's national executive for India.
Amgen’s expansion aligns with India’s growing role as the “pharmacy of the world,” attracting global pharmaceutical giants. The company’s presence in Hyderabad coincides with the BioAsia conference, where key executives from Amgen, Eli Lilly (NYSE: LLY), Novartis (SIX: NOVN), and leading Indian pharma firms will participate.
The U.S. and India recently initiated talks for a trade deal to strengthen collaboration in emerging technologies. U.S. Consul General in Hyderabad, Jennifer Larson, highlighted Amgen’s expansion as a prime example of this partnership. However, potential U.S. tariffs on pharmaceutical imports—reportedly 25% or higher—could impact Indian drugmakers, as the U.S. remains their largest market.
With Amgen’s strategic investment, India’s biotech sector continues to gain global attention, reinforcing its position as a key hub for pharmaceutical innovation.
